Osmotica Pharmaceuticals PLC (OSMT)
| Market Cap | 149.63M |
| Revenue (ttm) | 127.09M |
| Net Income (ttm) | -90.85M |
| Shares Out | 62.77M |
| EPS (ttm) | -1.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 641,612 |
| Open | 1.99 |
| Previous Close | 2.02 |
| Day's Range | 1.93 - 2.02 |
| 52-Week Range | 1.83 - 6.38 |
| Beta | 2.25 |
| Analysts | Buy |
| Price Target | 5.50 (+183.5%) |
| Est. Earnings Date | Nov 15, 2021 |
About OSMT
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase...
Financial Performance
In 2020, OSMT's revenue was $177.88 million, a decrease of -25.89% compared to the previous year's $240.03 million. Losses were -$79.59 million, -70.62% less than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OSMT stock is "Buy." The 12-month stock price forecast is 5.50, which is an increase of 183.51% from the latest price.
News
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 20...
Here's why Osmotica Pharmaceuticals is down 35% on Thursday
Shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) tanked more than 35% on Thursday as the company priced its underwritten public offering of 14 million ordinary shares at a discount. Osmotica to gen...
Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million
BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered in...
Osmotica Under Pressure On $35M Equity Raise To Pay Off Debt
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) has priced its secondary public offering of 14 million shares and warrants to purchase up to 14 million shares at $2.5/piece. Gross proceeds are expected to b...
Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering
BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its pre...
Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering
BRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced ...
Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021
BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, ...
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference
BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian ...
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
-- Divestiture advances Company's transformation and emphasis on eye care and ocular aesthetics -- -- Proceeds of the sale will be used to retire a substantial portion of outstanding debt --
OSMOTICA PHARM (OSMT) Reports Q2 Loss, Lags Revenue Estimates
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -66.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Osmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business Update
Sale of legacy business to Alora Pharmaceuticals, LLC expected to close in third quarter 2021
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021
BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian M...
Osmotica Pharmaceuticals plc to Provide Second Quarter 2021 Business and Financial Update on August 16, 2021
BRIDGEWATER, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Com...
Will OSMOTICA PHARM (OSMT) Report Negative Q2 Earnings? What You Should Know
OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Osmotica Subsidiary RVL Pharmaceuticals, Focused on Eye Care and Ocular Aesthetics, Strengthens and Expands Leadershi...
BRIDGEWATER, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that J. Aaron ...
Osmotica Stock Surges On $170M Divestiture Deal With Alora Pharmaceuticals
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) has agreed to sell its portfolio of legacy products and Georgia manufacturing facility, for up to $170 million, to Alora Pharmaceuticals LLC. Osmotica will re...
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business...
Osmotica will receive a $110 million upfront cash payment, with the potential to receive up to $60 million in additional milestone payments Alora will acquire manufacturing operations in Marietta, Georg...
Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
BRIDGEWATER, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced results of t...
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Healthcare Conference 2021
BRIDGEWATER, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Ma...
OSMOTICA PHARM (OSMT) Reports Q1 Loss, Lags Revenue Estimates
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 34.78% and -25.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Osmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Ma...
RVL Pharmaceuticals Upneeq® Wins 2021 MedTech Breakthrough Award
Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies
Osmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021
BRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Comp...
Analysts Estimate OSMOTICA PHARM (OSMT) to Report a Decline in Earnings: What to Look Out for
OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.